Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Lamotrigine (LTG), a phenyltriazine derivative and anti-epileptic drug, has emerged as an effective first-line treatment for bipolar mood disorder. Like the other mood stabilizers lithium and valproate, LTG also has neuroprotective properties but its exact mechanisms remain poorly defined. The present study utilized rat cerebellar granule cells (CGCs) to examine the neuroprotective effects of LTG against glutamate-induced excitotoxicity and to investigate potential underlying mechanisms. CGCs pretreated with LTG were challenged with an excitotoxic dose of glutamate. Pretreatment caused a time- and concentration-dependent inhibition of glutamate excitotoxicity with nearly full protection at higher doses (⩾100 µm), as revealed by cell viability assays and morphology. LTG treatment increased levels of acetylated histone H3 and H4 as well as dose- and time-dependently enhanced B-cell lymphoma-2 (Bcl-2) mRNA and protein levels; these changes were associated with up-regulation of the histone acetylation and activity of the Bcl-2 promoter. Importantly, lentiviral-mediated Bcl-2 silencing by shRNA reduced both LTG-induced Bcl-2 mRNA up-regulation and neuroprotection against glutamate excitotoxicity. Finally, the co-presence of a sub-effective concentration of LTG (10 µm) with lithium or valproate produced synergistic neuroprotection. Together, our results demonstrate that the neuroprotective effects of LTG against glutamate excitotoxicity likely involve histone deacetylase inhibition and downstream up-regulation of anti-apoptotic protein Bcl-2. These underlying mechanisms may contribute to the clinical efficacy of LTG in treating bipolar disorder and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 2×
“We therefore hypothesize that LTG may act by indirect mechanisms to inhibit HDAC activity, such as through downstream signalling cascades or metabolic products, as opposed to the direct inhibitory actions of VPA (Phiel et al. 2001).”
BackgroundCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate
Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S., et al. (2009) · Science · doi:10.1126/science.1176709 · Cited by 997
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript and traumatic brain injury, among others (for review, see Doble, 1999).”
BackgroundMultiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676 · cited 5×
“…inhibition is well-characterized as a primary mechanism of VPA-induced neuroprotection, and HDAC inhibitors including sodium butyrate and tri-chostatin A have been shown to regulate the expression of neuroprotective factors through histone hyperacetylation (for review, see Chuang et al. 2009).”
BackgroundInfluentialSelf-citationLithium-induced increase in human brain grey matter
Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G., & Menji, H. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02793-8 · Cited by 649 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript increases total grey matter volume (Moore et al. 2000 b) and enhances levels of N-acetylaspartate, a marker of neuronal viability, in the brains of bipolar patients (Moore et al. 2000a); these structural changes…”
BackgroundGlutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408 · cited 1×
“Specifically, the accumulation of data connecting glutamate and glutamate receptors to depression (Paul & Skolnick, 2003) suggests that the shared anti-glutamatergic properties of lithium, VPA, and LTG – all involving up-regulation of Bcl-2 – may contribute to their efficacy against depressive…”
BackgroundWang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., Huang, L., Liu, Y., Zhang, L., & Qin, C. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.08.006 · Cited by 271 · cited 2×
“2009) as well as the post-transcriptional regulation of Bcl-2 (e.g. Cimmino et al. 2005; Wang et al. 2009).”
BackgroundKosten, T. A., Galloway, M. P., Duman, R. S., Russell, D. S., & D'Sa, C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301527 · Cited by 165 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript models of depressive-like behaviour, result in down-regulation of Bcl-2 mRNA in key brain regions (Bravo et al. 2009; Kosten et al. 2008).”
BackgroundRohn, T. T., Vyas, V., Hernandez-Estrada, T., Nichol, K. E., Christie, L.-A., & Head, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5620-07.2008 · Cited by 146 · cited 1×
“…protein, Bcl-2 levels decrease as early as 6 h after glutamate challenge in neurons (Liu & Zhu, 1999) and its overexpression is associated with protection against apoptosis in multiple cellular and animal models of neuronal injury (Rohn et al. 2008; Vukosavic et al. 2000; Yuan et al.2003).”
Background
Cited by
Naoi, M., Maruyama, W., & Shamoto-Nagai, M. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1709-8 · Cited by 173
“Antidepressants and mood stabilizers also increase anti-apoptotic Bcl-2 expression (Creson et al. 2009; Leng et al. 2013).”
BackgroundA five‐year follow‐up study of neurocognitive functioning in bipolar disorder
Santos, J. L., Aparicio, A., Bagney, A., Sánchez‐Morla, E. M., Rodríguez‐Jiménez, R., Mateo, J., & Jiménez‐Arriero, M. Á. (2014) · Bipolar Disorders · doi:10.1111/bdi.12215 · Cited by 93
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“It blocks voltage-gated sodium channels, thus inhibiting glutamate release, inhibits AMPA receptors, is an indirect inhibitor of histone deacetylases (HDACs) and robustly induces the prominent neuroprotective protein Bcl-2 [109].”
BackgroundSelf-citationInvestigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology
Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M. L., & Dean, O. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.004 · Cited by 38
Metadata
- Authors
- Leng, Y., Fessler, E. B., & Chuang, D.-M.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-01
- Volume
- 16
- Issue
- 3
- Pages
- 607-620
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2161297645
- Cited by
- 51
- References
- 11
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. https://app.cochat.ai/papers/10.1017/s1461145712000429
- The paper
- Leng, Y., Fessler, E. B., & Chuang, D.-M. (2013). Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145712000429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.